Abstract: Disclosed herein is an albumin pharmaceutical composition, comprising albumin and at least one amino acid having a relative molecular mass of 145-175. Clinically, the albumin pharmaceutical composition can effectively reduce undesirable responses, such as rash, urticaria, anaphylaxis and possible immune responses in the human body caused by albumin polymers and dimers, thereby further ensuring the safety in clinical medication.

Abstract: Embodiments of the present disclosure relate to solutions for reducing interference and optimizing parameter. A first device measures interference on a frequency resource in a scheduling interval. If strength of the interference exceeds a threshold, the first device determines an interfering device by using a model trained with strength of previous interference and previous scheduling information of a plurality of candidate devices. In this way, the interfering device may be identified accurately and quickly and the interference may be reduced accordingly. In addition, a second device determines and transmits performance information to a third device. Then, the second device receives a parameter for adjusting transmission power from a third device. The parameter is determined based on respective performance information of a plurality of devices comprising the second device to maximum overall performance of the plurality of devices. In this way, the overall performance of the communication is improved.

Abstract: Disclosed herein is an albumin pharmaceutical composition, comprising albumin and at least one amino acid having a relative molecular mass of 145-175.

Abstract: Disclosed herein is an albumin pharmaceutical composition, comprising albumin and at least one amino acid having a relative molecular mass of 145-175. Clinically, the albumin pharmaceutical composition can effectively reduce undesirable responses, such as rash, urticaria, anaphylaxis and possible immune responses in the human body caused by albumin polymers and dimers, thereby further ensuring the safety in clinical medication.

Abstract: Disclosed herein is an albumin pharmaceutical composition, comprising albumin and at least one amino acid having a relative molecular mass of 145-175. Clinically, the albumin pharmaceutical composition can effectively reduce undesirable responses, such as rash, urticaria, anaphylaxis and possible immune responses in the human body caused by albumin polymers and dimers, thereby further ensuring the safety in clinical medication.